Clinical Trial Update: CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I) [EARLY_Phase 1]

View source ↗

Summary

Investigator-initiated Phase 1 trial evaluating a CRISPR/cas13-mediated RNA targeting therapy for neovascular age-related macular degeneration, currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• CRISPR/cas13-mediated RNA targeting therapy

Snippet

Sponsor: HuidaGene Therapeutics Co., Ltd. | Conditions: Neovascular Age-related Macular Degeneration(nAMD) | EARLY_Phase 1 | Status: RECRUITING